Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maya H Buch

Showing results (51-60 of 180) with videos related to

Pageof 18
Sort By:
Arthritis and Rheumatism|March 17, 2004
Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor alpha blockadeMaya H Buch, Sarah J Bingham, Yohei Seto, et al.
RMD Open|May 5, 2017
Ultrasound-detectable grey scale synovitis predicts future fulfilment of the 2010 ACR/EULAR RA classification criteria in patients with new-onset undifferentiated arthritisSarah C Horton, Ai Lyn Tan, Richard J Wakefield, et al.
Arthritis and Rheumatism|May 30, 2009
Re-treatment of rheumatoid arthritis patients who were initial nonresponders to rituximab: comment on the article by Thurlings et alEdward M Vital, Shouvik Dass, Maya H Buch, et al.
Annals of the Rheumatic Diseases|January 8, 2014
Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritisCécile Gaujoux-Viala, Jackie Nam, Sofia Ramiro, et al.
Rheumatology and Therapy|December 19, 2022
Analysis of Disease Activity Metrics in a Methotrexate Withdrawal Study among Patients with Rheumatoid Arthritis Treated with Tofacitinib plus MethotrexateRoy Fleischmann, Boulos Haraoui, Maya H Buch, et al.
Annals of the Rheumatic Diseases|March 21, 2013
The enhanced liver fibrosis test: a clinical grade, validated serum test, biomarker of overall fibrosis in systemic sclerosisGiuseppina Abignano, Giovanna Cuomo, Maya H Buch, et al.
RMD Open|July 14, 2024
What role do socioeconomic and clinical factors play in disease activity states in rheumatoid arthritis? Data from a large UK early inflammatory arthritis auditMaryam Adas, Mrinalini Dey, Sam Norton, et al.
Rheumatology (Oxford, England)|March 22, 2016
Discordance between the predictors of clinical and imaging remission in patients with early rheumatoid arthritis in clinical practice: implications for the use of ultrasound within a treatment-to-target strategySarah C Horton, Ai Lyn Tan, Jane E Freeston, et al.
RMD Open|September 30, 2020
Risk of venous thromboembolism in immune-mediated inflammatory diseases: a UK matched cohort studyJames Galloway, Kevin Barrett, Peter Irving, et al.
Rheumatology (Oxford, England)|January 6, 2021
Changes in the pharmacological management of rheumatoid arthritis over two decadesSamantha S R Crossfield, Maya H Buch, Paul Baxter, et al.
Pageof 18

Showing results (51-60 of 180) with videos related to

Sort By:
Pageof 18
Arthritis and Rheumatism|March 17, 2004
Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor alpha blockadeMaya H Buch, Sarah J Bingham, Yohei Seto, et al.
RMD Open|May 5, 2017
Ultrasound-detectable grey scale synovitis predicts future fulfilment of the 2010 ACR/EULAR RA classification criteria in patients with new-onset undifferentiated arthritisSarah C Horton, Ai Lyn Tan, Richard J Wakefield, et al.
Arthritis and Rheumatism|May 30, 2009
Re-treatment of rheumatoid arthritis patients who were initial nonresponders to rituximab: comment on the article by Thurlings et alEdward M Vital, Shouvik Dass, Maya H Buch, et al.
Annals of the Rheumatic Diseases|January 8, 2014
Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritisCécile Gaujoux-Viala, Jackie Nam, Sofia Ramiro, et al.
Rheumatology and Therapy|December 19, 2022
Analysis of Disease Activity Metrics in a Methotrexate Withdrawal Study among Patients with Rheumatoid Arthritis Treated with Tofacitinib plus MethotrexateRoy Fleischmann, Boulos Haraoui, Maya H Buch, et al.
Annals of the Rheumatic Diseases|March 21, 2013
The enhanced liver fibrosis test: a clinical grade, validated serum test, biomarker of overall fibrosis in systemic sclerosisGiuseppina Abignano, Giovanna Cuomo, Maya H Buch, et al.
RMD Open|July 14, 2024
What role do socioeconomic and clinical factors play in disease activity states in rheumatoid arthritis? Data from a large UK early inflammatory arthritis auditMaryam Adas, Mrinalini Dey, Sam Norton, et al.
Rheumatology (Oxford, England)|March 22, 2016
Discordance between the predictors of clinical and imaging remission in patients with early rheumatoid arthritis in clinical practice: implications for the use of ultrasound within a treatment-to-target strategySarah C Horton, Ai Lyn Tan, Jane E Freeston, et al.
RMD Open|September 30, 2020
Risk of venous thromboembolism in immune-mediated inflammatory diseases: a UK matched cohort studyJames Galloway, Kevin Barrett, Peter Irving, et al.
Rheumatology (Oxford, England)|January 6, 2021
Changes in the pharmacological management of rheumatoid arthritis over two decadesSamantha S R Crossfield, Maya H Buch, Paul Baxter, et al.
Pageof 18